Register for our free email digests:
Schepens Eye Research Institute
Division of Massachusetts Eye & Ear Infirmary
Latest From Sylentis SA
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.
Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.
Yondelis (trabectedin), for the treatment of metastatic or advanced soft tissue sarcoma, drove business for the Spanish biotech group Zeltiaduring the first nine months of 2008.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.